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Background: We measured anti-transglutaminase (anti-
tTG) antibody in the culture medium of intestinal biopsy
specimens from patients with suspected celiac disease
(CD) and evaluated the relationship between antibody
production and severity of intestinal mucosal damage.
Methods: We performed diagnostic testing for CD on
273 consecutive patients. In addition to routine histo-
logic evaluation of duodenal biopsy specimens, we
assayed anti-tTG antibodies in serum and in the culture
medium of duodenal biopsy specimens.
Results: CD was diagnosed in 191 of the 273 patients.
Sensitivity and specificity of the serum anti-endomy-
sium (EmA) and anti-tTG assays were 83% and 85% and
99% and 95%, respectively, and both had 88% diagnostic
accuracy. EmA and anti-tTG assayed in the culture
medium had 98% sensitivity, 100% specificity, and 98%
diagnostic accuracy (vs serum assays; P <0.0001). Twen-
ty-nine CD patient specimens (16%) were negative for
serum anti-tTG and EmA; for 24 of these patients,
anti-tTG assay of the culture medium was positive. The
CD patients whose biopsy specimens were positive for
serum antibodies showed the following intestinal his-
tologies: total villous atrophy, 35%; severe villous atro-
phy, 25%; mild atrophy, 25%; villi with no atrophy but
with increased intraepithelial lymphocytes, 15%. None
of the CD patients whose specimens were negative for
serum antibodies showed total or severe villous atro-
phy; 77% had mild villous atrophy, and 23% had no
villous atrophy but had increased intraepithelial lym-
phocyte counts. Mild villous atrophy was also seen in
specimens from 15% of patients without CD.
Conclusion: Anti-tTG assay of the culture medium of
biopsy specimens can improve the accuracy of CD
diagnosis in patients negative for serum antibodies.
© 2006 American Association for Clinical Chemistry
Celiac disease (CD)6 is one of the most common chronic
diseases among Caucasians, occurring in 1 in 100 to 300
individuals in Europe and the United States (1–4). Diag-
nosis is based on the histologic findings of hyperplastic
villous atrophy while the patient is eating gluten and
subsequent full clinical remission after the exclusion of
gluten from the diet (5 ). Because CD patients may have
intestinal mucosal lesions less severe than the typical
diagnostic “subtotal or total villous atrophy”, various
degrees of intestinal damage, including simple mucosal
inflammation with minimal villous damage, are now
considered as indications of possible CD (6 ). Conse-
quently, the presence of circulating antibodies, mainly
anti-transglutaminase (anti-tTG) and anti-endomysium
(EmA) antibodies, on diagnosis and their disappearance
when the patient is following a gluten-free diet are consid-
ered important data to support the CD diagnosis in cases
withmild intestinal lesions. According to the original criteria
of the European Society of Pediatric Gastroenterology and
Nutrition (ESPGAN) (7), a gluten challenge and several
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intestinal biopsies must be performed in patients without a
definitive initial CD diagnosis, i.e., who do not have marked
intestinal damage or serum anti-tTG and EmA.
We recently showed that assay of the culture medium of
intestinal biopsy specimens for EmA antibodies can identify
an infiltrative/hyperplastic histologic pattern that occurs in
CD patients but is often associated with negative serum
EmA assay results (8). This finding suggests that in patients
with negative serology but with symptoms consistent with
CD, an EmA assay of the culture medium of biopsy samples
should be performed to help confirm the diagnosis.
We measured anti-tTG antibodies in the culture me-
dium of intestinal biopsy specimens from patients with
suspected CD and assessed the diagnostic value of this
assay. The relationship between the severity of the intes-
tinal mucosal damage and the production of anti-tTG
antibodies was also evaluated.
Patients and Methods
This prospective study included 120 children (50 males,
70 females; age range, 7 months to 14 years; median age,
14 months) and 153 adults (54 males, 99 females; age
range, 17–80 years; median age, 32 years), enrolled from
January 2001 to June 2003, who were consecutive patients
undergoing intestinal biopsy for suspected CD at 2 cen-
ters: a pediatric gastroenterology clinic and an internal
medicine clinic. Inclusion criteria were positivity for se-
rum IgA EmA and/or anti-tTG antibodies or, in patients
with negative serum EmA and anti-tTG assay results, loss
of duodenal plicae and the presence of mucosal scalloping
observed during esophagogastroduodenoscopy per-
formed for any reason, or presence of one or more of the
following symptoms without evidence of a disease other
than CD after a complete work-up: weight loss or failure
to thrive, anemia, chronic diarrhea, or abdominal pain.
The diagnostic work-up may also have included routine
hematochemical assays, a thyroid study, serum autoanti-
bodies, abdominal ultrasonography and/or computed
tomography, colonoscopy, small-intestine barium exami-
nation, H2 breath test, duodenal fluid microbiological
evaluation, and bone marrow biopsy.
Patients who had undergone previous histologic eval-
uation for suspected CD were excluded from the study.
All adult patients included in the study were followed as
outpatients, whereas the children were hospitalized.
In the patients with positive serum anti-tTG and/or
EmA assay results, CD diagnosis was based on the
appearance of clinical symptoms and histologic indica-
tions of intestinal damage while patients were on a
gluten-containing diet and the disappearance of the
symptoms and normalization of serum anti-tTG and/or
EmA antibodies on a gluten-free diet. In the pediatric and
adult patients negative for serum anti-tTG and EmA
antibodies, diagnosis was based on clinical symptoms and
histologic indications of damage on a gluten-containing
diet, the disappearance of the symptoms and normaliza-
tion of the intestinal histologic findings on a gluten-free
diet, and reappearance of the symptoms and mucosal
damage on gluten challenge.
The protocol was approved by the Ethics Committee of
the University Hospital of Palermo, and informed consent
was obtained from the patients involved in the study or
from their parents in the case of the pediatric patients.
serology studies
Serum IgA was measured by ELISA to exclude IgA
deficiency. Serum IgA recombinant anti-human tTG anti-
body concentrations were determined with a commer-
cially available ELISA (human Eu-tTG IgA; Eurospital)
(9 ). Results were expressed as a percentage of the positive
control serum. Reference values were taken as 7%,
representing a value2 SD above the mean of 850 healthy
individuals. Serum IgA EmA antibodies were assayed
with a commercially available indirect immunofluores-
cence method on monkey esophagus (Anti-endomysium;
Eurospital) as described previously (9, 10).
duodenalmucosa cultureandassays for IgAEmA
and anti-tTG antibodies in culture medium
Six duodenal biopsy samples were obtained from each
patient by esophagogastroduodenoscopy. Four samples
underwent routine histologic evaluation, and 2 specimens
were cultured for 72 h at 37 °C with a commercial reagent
set (anti-Endomysium-biopsy; Eurospital), as described
previously (8 ). One sample was cultured in the presence
of the 31–43 gliadin peptide (0.1 g/L) and the other
without its addition. Culture supernatants were collected
and stored at 80 °C until used. IgA EmA antibodies in
undiluted supernatants were determined by the same
commercial reagent set used for serum EmA antibodies,
and the positive samples were titered with progressive
dilutions until they became negative.
The concentrations of the IgA recombinant anti-human
tTG antibodies in supernatants were determined in the
Eurospital laboratory with a new commercial ELISA
(Eu-tTG-biopsy; Eurospital). Recombinant h-tTG antigen
diluted in phosphate-buffered saline was used to coat the
wells. The purity of the recombinant protein was assessed
by sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis. The culture medium from the EmA biopsy was
diluted 1:5. The conjugate was diluted to obtain reliable
absorbances. Absorbance was read in a microplate reader
at 450 nm. Anti-tTG values in the supernatants were
expressed as absorbance. Reference values were taken as
300, representing a value 2 SD above the mean of 200
healthy individuals. The intraassay CV for the IgA h-tTG
autoantibody ELISA on culture medium was 3.2% (n 
20), and the interassay CV was 5.4% (n  20).
IgA EmA and anti-tTG assays of the culture medium
were performed by personnel unaware of the clinical and
laboratory data of the patients.
A control test performed in our laboratory on 20
culture media in which IgA EmA and anti-tTG antibodies
were first assayed on fresh medium and then 6 months
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later after storage at 80 °C showed that storage did not
significantly alter the results obtained: EmA results were
identical, and the interassay CV for IgA anti-tTG was 7.1%
(n  30).
intestinal biopsy and histology
Biopsy specimens were obtained from the second duode-
nal portion during gastroduodenoscopy. Specimens ade-
quate in size were immediately oriented with the aid of a
stereomicroscope and subsequently embedded in paraffin
(8–10). The slides were stained with hematoxylin and
eosin and graded according to the standardized scheme
reported by Oberhuber et al. (6 ). The number of intraepi-
thelial lymphocytes (IELs) per 100 villous epithelial cells
was assessed as described by Ferguson and Murray (11 );
the upper limit of the reference interval in our laboratory
is 30 IELs/100 epithelial cells. In all cases, histologic
analysis was performed by an examiner unaware of the
clinical condition and laboratory test results of the pa-
tients.
statistical analysis
We followed the STARD checklist for studies on the
diagnostic accuracy of tests (12 ). The sensitivity, specific-
ity, and diagnostic accuracy of the methods examined
were calculated by standard statistical methods (13 ). The
Fisher exact test was used to compare the sensitivity,
specificity, and diagnostic accuracy of the assays. The
Spearman correlation coefficient was calculated to evalu-
ate the relationship between anti-tTG values and EmA
titers assayed in the culture medium. The 2 test for trend
was used to compare the percentages of the different
intestinal mucosa lesions in the CD patients with positive
serology, in the CD patients with negative serology, and
in the non-CD patients.
Results
final diagnoses in the study group
None of the patients enrolled refused to undergo intesti-
nal biopsy, and none showed IgA deficiency. Data for the
adult and pediatric patients, grouped according to the
different inclusion criteria and the final diagnoses, are
shown in Table 1. Histologic findings and the clinical
follow-up confirmed that 162 of the 166 patients positive
for serum EmA and/or anti-TG antibodies had CD. The
other 4 patients (1 positive for EmA and anti-tTG antibod-
ies, and 3 positive only for anti-tTG antibodies) in whom
CD diagnosis was excluded showed a normal duodenal
histology, with a villi/crypts ratio3.5 and30 IELs/100
epithelial cells (range, 12–20).
Among the patients who underwent intestinal histo-
logic evaluation and were negative for serum EmA and
tTG antibodies, CD was diagnosed in 13 of 83 adults and
16 of 24 children. Duodenal histologic findings were
compatible with CD diagnosis at entry to the study:
symptoms disappeared and duodenal histologic findings
normalized on a gluten-free diet, and symptoms and
mucosal damage reappeared on gluten challenge.
In total, 81 adults and 110 children had a final diagno-
sis of CD. In the adult patients, 72 had diagnoses other
than CD (more than 1 diagnosis was present in each
patient): sideropenic anemia (66 cases), irritable bowel
syndrome (58 cases), peptic ulcers (30 cases), multiple
food hypersensitivity (19 cases), systemic erythematous
lupus (3 cases), rheumatoid arthritis (1 case), intestinal
giardiasis (2 cases), autoimmune enteropathy (1 case), and
refractory sprue (1 case). The 10 children without CD had
the following final diagnoses: cow’s milk protein intoler-
ance (5 cases), multiple food intolerance (3 cases), insulin-
dependent diabetes mellitus (1 case), and intestinal giar-
diasis (1 case).
results of IgA EmA and anti-tTG assays of the
culture medium
Assays for IgA EmA and anti-tTG antibodies in the
culture medium of the intestinal biopsy specimens
showed an identical pattern: all cases positive for EmA
antibodies were also positive for anti-tTG antibodies, and
all cases negative for EmA antibodies were also negative
for anti-tTG antibodies. The results were not modified
when the 31–43 peptide was added to the culture me-
dium; there was no difference between the assays per-
formed on the culture medium with or without added
peptide. As shown in Fig. 1, we found a highly significant
Table 1. Number of adult and pediatric patients divided according to the different inclusion criteria and the
final diagnoses.a
Final diagnosis of CD, n (%) Final diagnosis other than CD, n (%)
Adults
Patients with positive serum EmA and/or tTG (n  70) 68 (97) 2 (3)
Patients with negative serum EmA and tTG (n  83) 13 (16) 70 (84)
Total (n  153) 81 (53) 72 (47)
Children
Patients with positive serum EmA and/or tTG (n  96) 94 (98) 2 (2)
Patients with negative serum EmA and tTG (n  24) 16 (67) 8 (33)
Total (n  120) 110 (92) 10 (8)
a The patients negative for serum EmA and/or anti-tTG were included in the study because they showed symptoms or esophagogastroduodenoscopic findings
suggesting a diagnosis of CD.
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statistical correlation between the EmA titer and the
absorbance obtained in the anti-tTG assay of the culture
medium of the intestinal biopsies of the CD patients,
without added 31–43 gliadin peptide [Spearman correla-
tion coefficient (R2)  0.905; P 0.0001].
behavior of EmA and anti-tTG antibodies in
assays of the culture medium of intestinal
biopsy specimens from cd and non-cd patients
All CD patients, both children and adults, positive for
serum EmA and/or anti-tTG antibodies were also posi-
tive for EmA and anti-tTG antibodies in the culture
medium. Furthermore, in 24 of the 29 CD patients nega-
tive for serum EmA and anti-tTG antibodies (all 16
children and 8 of the 13 adult patients), both of these
antibodies were positive in the culture medium of the
intestinal biopsy specimens. None of the patients with a
final diagnosis other than CD had positive EmA and
anti-tTG assay results for the culture medium, including
the 2 adults (1 with systemic erythematous lupus and 1
with rheumatoid arthritis) and 2 children (with intestinal
giardiasis and insulin-dependent diabetes mellitus, re-
spectively) whose results were false positive for serum
EmA and/or anti-tTG antibodies. A cross-tabulation of
the results for serum EmA and anti-tTG antibodies and
anti-tTG antibodies in the culture medium of the intesti-
nal biopsies, according to final diagnosis, is shown in
Table 2.
diagnostic accuracy of EmA and anti-tTG
assays of serum and culture medium
Shown in Table 3 are the sensitivity, specificity, and
diagnostic accuracy for diagnosing CD based on the
results of the assays for serum EmA and serum anti-tTG
antibodies, together with assays for EmA and anti-tTG in
the culture medium of the intestinal biopsy specimens.
Although the specificities of the serum and culture me-
dium assays did not differ, the sensitivity and diagnostic
accuracy were significantly higher for the culture medium
assays (P 0.0001 for both, Fisher exact test).
relationship between serum EmA and anti-tTG
results and severity of damage to intestinal
mucosa
The intestinal histologic findings for the 273 consecutive
patients who underwent intestinal biopsy for suspected
CD, according to the final diagnoses and the behavior of
the serum EmA and anti-tTG antibodies, are presented in
Fig. 2.
CD patients with positive serum EmA and/or anti-tTG
assay results clearly showed more severe intestinal mu-
cosal lesions; severe or total villous atrophy (grade 3b or
3c) was seen in 25% and 35% of this group, respectively
(vs seronegative CD patients, P 0.001; vs non-CD pa-
tients, P 0.0001). Mild villous atrophy (grade 3a) was
seen in 25% of these patients, and 15% of them showed
only an increase in the IEL number without a significant
reduction in villi height (grade 2 lesions). Anti-tTG anti-
bodies assayed in the culture medium were positive in all
of these patients. Intestinal mucosal damage was less
severe in the 29 CD patients with negative serum EmA
and anti-tTG antibodies: none of them showed total
villous atrophy, 77% had mild villous atrophy (grade 3a),
and 23% had only an increase in IEL number without
villous damage (grade 2 lesion). Anti-tTG antibodies
assayed in the culture medium were positive in 24 of
these patients, as only 5 patients with grade 2 lesions did
not show anti-tTG positivity.
In the patients without CD, mild villous atrophy was
seen in 11 cases: 5 children [multiple food hypersensitiv-
ity (3 cases), cow’s milk protein intolerance (1 case),
intestinal giardiasis (1 case)] and 6 adults [multiple food
intolerance (4 cases), systemic erythematous lupus (1
case), and autoimmune enteropathy (1 case)]. Another
adult patient with refractory sprue, who was never posi-
Fig. 1. Correlation between EmA titer (expressed as dilution coeffi-
cient) and anti-tTG antibody concentration (expressed as absorbance)
assayed in the culture medium of the intestinal biopsy specimens from
191 consecutive patients who underwent intestinal biopsy and had a
final diagnosis of CD.
Equation for the line: y  650.64x (R2  0.9058)
Table 2. Cross-tabulation of the serum EmA, serum anti-
tTG, and culture medium anti-tTG assay results in patients
with suspected CD, divided according to the
final diagnoses.
CD, n Non-CD, n Total, n
Serum EmA
Positive 159 1 160
Negative 32 81 113
Total 191 82 273
Serum anti-tTG
Positive 162 4 166
Negative 29 78 107
Total 191 82 273
Culture medium anti-tTG
Positive 186 0 186
Negative 5 82 87
Total 191 82 273
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tive for serum EmA, anti-tTG, or anti-enterocyte antibod-
ies, showed severe villous atrophy. In 58% of this patient
group, we observed slight intestinal mucosal lesions,
characterized by normal villi but a high IEL number
(40–65 IELs/100 enterocytes). None of the non-CD pa-
tients had a positive result for anti-tTG antibodies in the
culture medium.
Discussion
The serologic tests for CD have 3 main roles in clinical
practice: (a) identifying individuals who require an intes-
tinal biopsy examination to diagnose the disease; (b)
supporting the diagnosis in individuals with characteris-
tic histologic features of CD; and (c) monitoring dietary
compliance. The first aspect seems to be fully confirmed
by recent reviews showing that serum IgA EmA antibod-
ies have 90%–100% sensitivity and 95%–100% specificity
and that IgA anti-tTG antibodies show very similar values
(14, 15), mainly obtained with the second-generation,
human anti-tTG assays (9, 16). However, the presence of
positive serum antibodies has been shown to correlate
with the degree of villous atrophy, and CD patients with
less severe histologic damage can be seronegative for CD
(17–20). It has been demonstrated previously that the
culture medium of intestinal biopsy specimens from some
of these CD patients showed positive EmA antibodies,
and this positivity can be useful for CD diagnosis in
patients with minimal intestinal histologic lesions (8, 21).
As tTG is known to be the sole (22 ) or main antigen of
EmA antibodies, in this study we aimed to assay anti-tTG
in the culture medium of intestinal biopsies from patients
with suspected CD. By applying standard criteria (5, 7) or
more rigorous criteria for cases with negative serum
antibodies, we made 191 new CD diagnoses. Approxi-
mately 15% of these (29 of 191 patients) were seronega-
tive, a frequency similar to that reported previously by
others (23 ). Interestingly, 24 of the 29 seronegative CD
patients were positive for EmA and anti-tTG antibodies
assayed in the culture medium of the intestinal biopsy
specimens. This result suggests that the assay for biopsy
specimen culture medium was more sensitive than the
serum assay. This higher sensitivity could be related to
the previously reported finding that EmA (24 ) and anti-
tTG (25 ) antibodies are produced by the intestinal mucosa
in CD patients. As a consequence, we hypothesize that for
cases with low antibody production, antibodies would
not be found in the serum but only in the primary site of
production. Therefore, the higher sensitivity of the culture
medium assay is associated with a higher diagnostic
accuracy. Furthermore, the 4 patients with false-positive
serum EmA or anti-tTG results had negative results in the
culture medium assay. The finding that 2 of these patients
were suffering from autoimmune diseases provides evi-
dence that serum anti-tTG results can be false positive in
these cases (9 ) and that the site of antibody production
may be other than intestinal (26 ).
Our results demonstrate the possibility of assaying
anti-tTG antibodies in the culture medium of intestinal
biopsy specimens and the concordance of these assay
results with the EmA assay, an important finding because
use of the EmA assay can be limited by increased costs,
time-consuming protocols, and above all, by the suscep-
tibility of the EmA assay to subjective interpretation,
which may lead to unacceptable variations between lab-
oratories.
Fig. 2. Intestinal histologic findings in the CD patients with positive
serum antibodies ( ; n 162), in those with negative serum EmA and
anti-tTG antibodies (f; n  29), and in the 82 patients with diseases
other than CD (
  
  
  ).
Severity of intestinal damage was classified according to a modified version of
the system used by Oberhuber et al. (6 ) as follows: type 0, normal mucosa; type
1, normal villi and crypt architecture, with 30 IELs/100 epithelial cells; type 2,
normal villi with crypt hyperplasia and 30 IELs/100 epithelial cells; type 3a,
mild villous flattening; type 3b, marked villous flattening; type 3c, total villous
flattening.
Table 3. Sensitivity, specificity, and diagnostic accuracy for CD diagnosis of serum EmA and anti-tTG assays and EmA and
anti-tTG assays of intestinal biopsy specimen culture medium.a
True positives,a n Sensitivity,b % True negatives,c n Specificity,b % Diagnostic accuracy,b %
Serum
EmA assay 159 83 (78–88) 81 99 (96–100) 88 (83–91)
Anti-tTG assay 162 85 (79–89) 78 95 (90–99) 88 (83–91)
Culture medium
EmA assay 186 98 (95–100) 82 100 (99–100) 98 (96–99)
Anti-tTG assay 186 98 (95–100) 82 100 (99–100) 98 (96–99)
a Total number of final CD diagnoses, n 191.
b Values in parentheses are the 95% confidence interval.
c Total number of final diagnoses other than CD, n  82.
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have practical clinical relevance because their results can
facilitate correct diagnosis. Our data show that the “sim-
ple” intestinal histologic evaluation does not allow defin-
itive CD diagnosis in cases in which serum antibodies are
not detected. In our study group, 23% of the seronegative
CD patients showed only increases in IEL numbers and
crypt hypertrophy without villous damage. Mild villous
atrophy was also seen in 15% of symptomatic patients
without CD, and 58% patients of these showed slight
intestinal mucosal lesions (normal villi but high IEL
number). According to the standard diagnostic criteria for
CD, all of these patients would have to undergo several
intestinal biopsies during different dietary treatment reg-
imens, including a gluten challenge. Because of the diag-
nostic accuracy of the assays performed on the culture
medium, the addition to the standard endoscopic proce-
dure of collection of an additional biopsy sample for in
vitro culturing of intestinal mucosa and subsequent anti-
tTG assay on the culture medium can simplify the diag-
nosis of CD and improve its accuracy. In clinical practice
we suggest use of the biopsy specimen antibody assay
method in all cases of suspected CD, even those negative
for serum anti-tTG or EmA antibodies, and in all other
suspected cases showing conflicting laboratory and histo-
logic data.
We thank Carole Greenall for valuable assistance in
revising the English. This study was supported by a grant
from the Ministero dell’Istruzione, dell’Universita` e della
Ricerca (MIUR) and Ministero delle Politiche Agricole e
Forestali (MiPAF): Project “Alimentazione e celiachia
(ALICE)” DD 86 (30-01-2002).
References
1. Catassi C, Fabiani E, Ratsch IM, Coppa GV, Giorgi PL, Pierdo-
menico R, et al. The celiac iceberg in Italy: a multicentre antigliadin
antibodies screening for celiac disease in school-age subjects.
Acta Pediatr Suppl 1996;412:29–35.
2. Kolho KL, Farkkila MA, Savilahti E. Undiagnosed celiac disease is
common in Finnish adults. Scand J Gastroenterol 1998;33:
1280–3.
3. Carlsson AK, Axelsson IE, Borulf SK, Bredberg AC, Ivarsson SA.
Serological screening for celiac disease in healthy 2.5-year-old
children in Sweden. Pediatrics 2001;107:42–5.
4. Not T, Horvath K, Hill ID, Partanen J, Hammed A, Magazzu G, et al.
Celiac disease risk in the USA: high prevalence of anti-endomy-
sium antibodies in healthy blood donors. Scand J Gastroenterol
1998;33:494–8.
5. Walker-Smith JA, Guandalini S, Schmitz J, Shmerling DH, Visakorpi
JK. Revised criteria for diagnosis of coeliac disease. Arch Dis Child
1990;65:909–11.
6. Oberhuber G, Granditsch G, Vogelsang H. The histopathology of
coeliac disease: time for a standardized report scheme for pathol-
ogists. Eur J Gastroenterol Hepatol 1999;11:1185–94.
7. Meuwisse GW. Diagnostic criteria in coeliac disease. Acta Paedi-
atr Scand 1970;59:461–3.
8. Carroccio A, Iacono G, D’Amico D, Cavataio F, Teresi S, Caruso C,
et al. Production of anti-endomysial antibodies in cultured duode-
nal mucosa: usefulness in coeliac disease diagnosis. Scand J
Gastroenterol 2002;37:32–8.
9. Carroccio A, Vitale G, Di Prima L, Chifari N, Napoli S, La Russa C,
et al. Comparison of anti-transglutaminase ELISAs and anti-
endomysial antibody assay in the diagnosis of celiac disease: a
prospective study. Clin Chem 2002;48:1546–50.
10. Carroccio A, Cavataio F, Iacono G, Agate V, Ippolito S, Kazmierska
I, et al. IgA anti-endomysial antibodies on the umbilical cord in
diagnosing celiac disease. Sensitivity, specificity and comparative
evaluation with the traditional kit. Scand J Gastroenterol 1996;
31:759–63.
11. Ferguson A, Murray D. Quantitation of intraepithelial lymphocytes
in human jejunum. Gut 1971;12:988–94.
12. Bruns DE, Huth EJ, Magid E, Young DS. Toward a checklist for the
reporting of studies of diagnostic accuracy of medical tests. Clin
Chem 2000;46:893–5.
13. Feinstein A. On the sensitivity, specificity and discrimination of
diagnostic tests. Clin Pharmacol Ther 1975;17:104–10.
14. Hill ID. What are the sensitivity and specificity of serologic tests
for celiac disease? Do sensitivity and specificity vary in different
populations? Gastroenterology 2005;128:S25–32.
15. Rostom A, Dube` C, Cranney A, Saloojee N, Sy R, Garritty C, et al.
The diagnostic accuracy of serologic tests for celiac disease: a
systematic review. Gastroenterology 2005;128:S38–46.
16. Van Meensel B, Hiele M, Hoffman I, Vermeire S, Rutgeerts P,
Geboes K, et al. Diagnostic accuracy of ten second-generation
(human) tissue transglutaminase antibody assays in celiac dis-
ease. Clin Chem 2004;50:2125–35.
17. Rostami K, Kerckhaert JP, Tiemessen R, Meijer JW, Mulder CJ.
The relationship between anti-endomysium antibodies and villous
atrophy in celiac disease using both monkey and human sub-
strate. Eur J Gastroenterol Hepatol 1999;11:439–42.
18. Dahele A, Kingstone K, Bode J, Anderson D, Ghosh S. Anti-
endomysial negative celiac disease: does additional serological
testing help? Dig Dis Sci 2001;46:214–21.
19. Tursi A, Brandimarte G, Giorgetti GM. Prevalence of anti-tissue
transglutaminase antibodies in different degrees of intestinal
damage in celiac disease. J Clin Gastroenterol 2003;36:219–21.
20. Dickey W, Hughes DF, McMillian SA. Sensitivity of serum tissue
transglutaminase antibodies for endomysial antibody positive and
negative celiac disease. Scand J Gastroenterol 2001;36:511–4.
21. Picarelli A, Di Tola M, Sabbatella L, Anania MC, Calabro A, Renzi
D, et al. Usefulness of the organ culture system in the in vitro
diagnosis of coeliac disease: a multicentre study. Scand J Gas-
troenterol 2006;41:186–90.
22. Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken E, et al.
Identification of tissue transglutaminase as the autoantigen of
celiac disease. Nat Med 1997;3:797–801.
23. Dickey W, Hughes DF, McMillian SA. Reliance on serum endomy-
sial antibody testing underestimates the true prevalence of celiac
disease by one fifth. Scand J Gastroenterol 2000;35:181–3.
24. Picarelli A, Maiuri L, Frate A, Greco M, Auricchio S, Londei M.
Production of anti-endomysial antibodies after in vitro gliadin
challenge of small intestine biopsy samples from patients with
celiac disease. Lancet 1996;348:1065–7.
25. Sblattero D, Florian F, Azzoni E, Not T, Ventura A, Bradbury A, et al.
Site of synthesis of antibodies to -gliadin and tissue transglu-
taminase in celiac disease patients [Abstract]. J Pediatr Gastro-
enterol Nutr 2000;31(Suppl 2):S214.
26. Picarelli A, Di Tola M, Sabbatella L, Vetrano S, Anania MC,
Spadaro A, et al. Anti-tissue transglutaminase antibodies in
arthritic patients: a disease-specific finding? Clin Chem 2003;49:
2091–4.
1180 Carroccio et al.: Anti-tTG Assay of Culture Medium
